Altimmune Company Insiders

Altimmune Management Team Effectiveness

The company has Return on Asset of (0.3956) % which means that on every $100 spent on assets, it lost $0.3956. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.7296) %, meaning that it generated no profit with money invested by stockholders. Altimmune's management efficiency ratios could be used to measure how well Altimmune manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.44 in 2024. Return On Capital Employed is likely to drop to -0.51 in 2024. Total Current Liabilities is likely to gain to about 21.2 M in 2024. Liabilities And Stockholders Equity is likely to gain to about 221.2 M in 2024Common Stock Shares Outstanding is likely to gain to about 55.9 M in 2024, despite the fact that Net Loss is likely to grow to (72.4 M).

Altimmune Workforce Comparison

Altimmune Insider Trading History

Altimmune Notable Stakeholders

The success or failure of an entity such as Altimmune often depends on how effective the management is. Altimmune management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Altimmune management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Altimmune management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Altimmune's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Altimmune. Check Altimmune's Beneish M Score to see the likelihood of Altimmune's management manipulating its earnings.

When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.